FDA denies Allergan's inhaled migraine drug; Carticept gets FDA nod for arthritis computer injection system;

> The FDA denied Allergan's inhaled version of the acute migraine drug dihydroergotamin, citing manufacturing concerns. Levadex is one of the drugs Allergan picked up in its buyout of Map Pharmaceuticals last year. Story

> Carticept Medical netted 510(k) clearance from the FDA for its Navigator Delivery System, a computer-controlled injection system for musculoskeletal injections. The system would help treat patients with arthritis. Release

> Researchers at Florida International University's Herbert Wertheim College of Medicine have developed a technique for delivering the anti-HIV drug AZTTP to the brain using magneto-electric nanoparticles. Release

> Bayer HealthCare began a Phase III trial of its inhaled amikacin solution BAY41-6551T to treat pneumonia in patients currently receiving intravenous antibiotics. Release

> EKOS released results of its trial comparing ultrasound-accelerated, catheter-directed thrombolysis to standard thrombolysis, with success in 80% of the cases. On average, the procedure was completed 12 hours earlier using the new procedure. Release

> A survey of 151 glaucoma patients showed that 74.2% stated a willingness to try a new injection method of treatment in place of topical medications. Nine of 10 patients who reported nonadherence said they would rather have the subconjunctival injections. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.